Background: To examine the clinical and economic burdens associated with delayed receipt of appropriate therapy among patients with Gram-negative bacteria (GNB) infections, stratified by antibiotic resistance status.
INTRODUCTION
A mong antibiotic-resistant strains of Gram-negative bacteria, carbapenem-resistant Enterobacteriaceae (CRE) have been identified as urgent public health threats; multidrug-resistant strains of Pseudomonas aeruginosa and extended spectrum beta-lactamase producing Enterobacteriaceae have been labeled as serious threats. 1 Despite considerable efforts to increase awareness of patients at risk for antibiotic-resistant Gramnegative infections, delayed appropriate therapy rates remain high for such patients and the negative consequences of delayed appropriate therapy have been welldocumented. [2] [3] [4] [5] [6] [7] [8] Although a link between delayed appropriate therapy and deleterious outcomes among patients with Gram-negative infections exists, it is unclear whether the association is causal or merely confounded by antibiotic resistance. Patients who receive delayed appropriate therapy are more likely to have an infection due to antibiotic-resistant pathogens, and patients with infections due to antibiotic-resistant pathogens have also been shown to experience poorer outcomes, including higher mortality rates, longer length of stay (LOS) and higher in-hospital costs versus patients with infections due to antibiotic-susceptible pathogens. 2, [8] [9] [10] It is also well-documented that patients with infections due to antibiotic-resistant pathogens tend to be sicker and have more comorbidities and other complicating conditions. 11, 12 To date, few studies have attempted to ascertain the contribution of delayed appropriate therapy on outcomes while minimizing the effect of antibiotic resistance. Thus, there is an outstanding need to determine whether delayed appropriate therapy is a primary and independent cause of poor outcomes, or whether the driver of poor outcomes is severe disease that is often associated with infections caused by resistant Gram-negative bacteria. This retrospective analysis of a large inpatient hospital database was undertaken to examine the clinical and economic burdens associated with delayed receipt of appropriate therapy among patients with infections due to Gram-negative bacteria, stratified by antibiotic resistance status.
METHODS WITH STATISTICAL CONSIDERATIONS

Study Design
The data source for this study was the Premier Hospital Database, which represents »20% of inpatient discharges (»50 million) in the United States and includes information for approximately 500 acute-care hospitals in the United States, including teaching and nonteaching institutions, as well as urban and rural facilities. 13 Admission records from 150 hospitals that provided microbiological data were included in this study. Information obtained from the database included primary and secondary diagnoses (in International Classification of Diseases, 9th Revision, Clinical Modification format), costs to the hospital to render care, healthcare utilization (medications administered, procedures, LOS and services rendered) and microbiological data. The Premier Hospital Database is compliant with the Health Insurance Portability and Accountability Act of 1996; all data are fully deidentified.
Patient Population
All hospital admissions of adults (aged ≥18 years) between July 1, 2011 and September 30, 2014 with evidence of a Gram-negative infection of interest (i.e., hospital-acquired pneumonia, complicated urinary tract infections, complicated intra-abdominal infections and bloodstream infections) were included if they had (1) a positive culture for Gram-negative bacteria from a site consistent with the infection type, and (2) had a LOS ≥1 days. Patients were excluded if they (1) were transferred from another hospital, (2) died or were discharged on the index date, (3) were pregnant or had evidence of childbirth at admission or (4) had evidence of infection with ecthyma gangrenosum, gangrene, necrotizing fasciitis, osteomyelitis or other chronic infection. Patients without relevant microbiological data or without evidence of receipt of antibiotics on the index date or within the subsequent 2-day period (i.e., a 3-day period overall) were also excluded.
Among patients with evidence of a Gram-negative infection of interest and who satisfied all other study criteria, the date of the earliest culture draw subsequently positive for ≥1 Gram-negative bacteria was deemed the index date. Patients were stratified by antibiotic susceptibility of isolated pathogens (i.e., resistant or susceptible group) from the culture drawn on the index date; those with evidence of ≥1 of the following resistant pathogens were deemed to have infection with a resistant organism: CRE, carbapenem-resistant Pseudomonas sp, multidrugresistant P aeruginosa and extended spectrum betalactamase producing Enterobacteriaceae. Timely appropriate therapy was defined as receipt on the index date or within the subsequent 2-day period of ≥1 antibiotic(s) with microbiological activity against all pathogens identified on the index culture (i.e., Gram-negative pathogens plus any other causal pathogens identified by culture); receipt of appropriate therapy on subsequent days was considered delayed.
Covariates and Outcome Measures
Patient-level covariates included age and sex; admission type and admitting source; measures related to healthcare utilization immediately before hospital admission that may cause immunosuppression and/or are associated with infections with resistant pathogens (e.g., receipt of chemotherapy or dialysis, prior invasive procedures[s], prior hospitalization[s]) 14 ; presumed source of infection (i.e., nosocomial, community-acquired or healthcare-associated); selected comorbidities (e.g., alcohol/ drug abuse, asthma, cerebrovascular disease, coronary heart disease and empyema); Charlson Comorbidity Index 15, 16 ; proxies for infection severity (e.g., in intensive care unit on index date); infection caused by ≥1 resistant pathogens (i.e., CRE, carbapenem-resistant Pseudomonas sp, multidrug-resistant P aeruginosa and/or extended spectrum beta-lactamase producing Enterobacteriaceae); and timely appropriate therapy versus delayed appropriate therapy. Hospital-level covariates included rural versus urban setting, teaching versus nonteaching facility, geographic area, number of beds and facility identification number. Outcomes of interest included duration of antibiotic therapy postindex culture, LOS in hospital postindex culture, costs to the hospital to render care postindex culture, discharge destination (home vs. other) and the composite outcome of in-hospital death or discharge to hospice.
Statistical Analyses
Comparisons between baseline characteristics of delayed and timely therapy groups within the susceptible and resistant patient populations used t test for continuous variables, chi-square test for nominal categorical variables and Wilcoxon rank sum for ordinal categorical variables.
Inverse probability-weighted estimators were used as weights in the regression models to obtain balanced distribution of characteristics between the groups of interest (delayed appropriate therapy versus timely appropriate therapy). 17, 18 Propensity scores were generated for each patient with an infection caused by Gram-negative bacteria on the index date by means of a multivariate logistic regression model that estimated for each patient the probability (a single variable bound by 0 and 1) of having delayed appropriate therapy or timely appropriate therapy. 19 All covariates were assessed to determine whether inclusion of the additional variable changed the estimate associated with the exposure of interest (delayed appropriate therapy) by >10%. Covariates that changed the estimate by >10% were retained for potential inclusion in a final multivariate model; all others were excluded. All covariates that modified the delayed appropriate therapyrelated estimate by >10% were then assessed for colinearity. Those with an absolute value for their correlation coefficient >0.6 were deemed colinear, in which case only the variable with the larger impact on the exposure of interest estimate was selected for the final multivariate model. For each population and outcome of interest, the multivariate model consisted of the exposure of interest plus all covariates that met the "10% criterion" and were deemed to not be colinear. Linear regression modeling was used to examine duration of antibiotic therapy, infection-related LOS in hospital and infection-related costs to hospital to render care. Logistic regression modeling was used to examine discharge destination (home vs. all other destinations) and in-hospital death or discharge to hospice.
RESULTS
Patients
Overall, 56,357 hospitalized patients with Gram-negative bacterial infections were included in the analysis: 6,055 patients with infections caused by resistant Gramnegative bacteria and 50,302 patients with infections caused by susceptible Gram-negative bacteria (Table 1) . Delayed appropriate therapy was received by 2,800 (46.2%) patients with resistant infections and 16,585 (33.0%) patients with susceptible infections.
Infection-related Outcomes in Patients With Resistant Pathogens
Among patients with infections due to resistant Gramnegative pathogens, demographics including age, sex and race were similar between the delayed appropriate therapy and timely appropriate therapy groups ( Delayed appropriate therapy was associated with significantly longer duration of antibiotic therapy (+4.5 days), longer LOS (+4.9 days) and higher in-hospital costs to hospital to render care (+$11,508) compared with those who received timely appropriate therapy (all, P < 0.01; Table 2 ). Delayed appropriate therapy was also associated with a 31% lower chance of being discharged to home and a 16% increase in risk of in-hospital mortality or being discharged to hospice.
Multivariate analysis showed that in patients infected with antibiotic-resistant pathogens, receipt of delayed appropriate therapy was associated with worse outcomes compared with receipt of timely appropriate therapy, including a 20% increase in the risk of in-hospital mortality or discharge to hospice, a decrease of 30% in the likelihood of being discharged to home, an increase of 50% in the duration of antibiotic therapy, an increase of 60% in LOS and an increase of 50% in total in-hospital costs to hospital to render care ( Figure 1A ).
Infection-related Outcomes in Patients With Susceptible Pathogens
Demographics including age, sex and race were similar between the delayed appropriate therapy and timely appropriate therapy groups among patients with infections due to susceptible Gram-negative pathogens ( Among patients with infections due to susceptible pathogens, delayed appropriate therapy was associated with significantly longer duration of antibiotic therapy (+4.9 days), longer LOS (+5.5 days) and higher in-hospital costs to hospital to render care (+$9,507) compared to those who received timely appropriate therapy (all, P < 0.01; Table 2 ). Delayed appropriate therapy was associated with a 35% decrease in the likelihood of being discharged to home and a 24% increase in risk of in-hospital mortality or being discharged to hospice.
Multivariate analysis showed that in patients infected with antibiotic-susceptible pathogens, outcomes were also adversely affected by receipt of delayed appropriate therapy: 20% increase in the risk of in-hospital mortality or discharge to hospice, a decrease of 30% in the likelihood of being discharged to home, an increase of 70% in the duration of antibiotic therapy, an increase of 80% in LOS and an increase of 80% in total in-hospital costs to hospital to render care ( Figure 1B ).
DISCUSSION
The results of this retrospective analysis of the Premier Hospital Database provide valuable information regarding outcomes for patients hospitalized for serious infections due to Gram-negative bacteria. First, the results highlight the relatively high incidence of delayed appropriate therapy among adult, hospitalized patients with either antibiotic-susceptible or -resistant infections due to Gram-negative pathogens (»34% of total population; »46% of patients with resistant infections). These alarmingly high rates call into focus the public health risk associated with delayed appropriate therapy and the urgent need to shift treatment practices away from escalation strategies that contribute to delayed appropriate therapy and toward early, relatively aggressive and comprehensive antibiotic therapy in patients with serious infections known or suspected to be of Gram-negative etiology. Early involvement of infectious diseases specialists may be the first step in ensuring early appropriate therapy. One recent study demonstrated significantly improved outcomes among patients who received care from infectious diseases specialists versus those who did not. 20 Most importantly, the findings from this study provide unique insights into the association between delayed appropriate therapy, infection susceptibility or resistance and outcomes among patients with Gram-negative infections. Although patients with serious infections due to Gram-negative bacteria who receive delayed appropriate therapy are typically found to have worse outcomes, it is difficult to discern whether it is causal. Most studies that evaluate the impact of delayed appropriate therapy include both antibiotic-resistant and -susceptible pathogens in the cohort; however, delayed appropriate therapy is correlated with patients with antibiotic resistance who tend to have poorer prognoses. [2] [3] [4] [5] [6] [7] [8] Cognizant of this, our study was designed to ascertain the association between delayed appropriate therapy and outcomes among patients with infections due to either antibiotic-resistant or -susceptible Gram-negative bacteria. In both populations, receipt of delayed appropriate therapy was associated with worse outcomes, including additional days of antibiotic therapy (1.5 and 1.8 additional days among patients with resistant and susceptible infections, respectively), LOS (1.6 and 1.8 additional days), additional total in-hospital costs ($11,508 and $9,507), an increased likelihood of the composite endpoint of in-hospital mortality or discharge to hospice (16% and 24%) and a decreased likelihood of discharge to home (31% and 35%). Interestingly, in multivariate analyses of patients with infections due to resistant or susceptible pathogens, the magnitude of the impact of delayed appropriate therapy on clinical and economic outcomes was approximately equivalent, including an »20% increased risk of the composite endpoint of inhospital mortality or discharge to hospice; an »70% increase in LOS; and an »65% increase in total in-hospital costs. This study surmounts the limitations of previous analyses and suggests that delayed onset of appropriate therapy is associated with poor outcomes, irrespective of resistance status of causal pathogen(s). Given that the magnitude of the incremental impacts associated with delayed appropriate therapy were similar, regardless of resistance status, our findings further highlight the importance of rapid pathogen identification, allowing for appropriate antibiotic(s) selection as early as possible in the treatment pathway.
Some factors regarding this analysis should be considered when interpreting the findings. First, it should be noted that in the multivariate analysis presented herein, in-hospital mortality was not analyzed as an individual Abbreviations: CRE, carbapenem-resistant Enterobacteriaceae; CRP, carbapenem-resistant Pseudomonas sp; ESBL, extended spectrum beta-lactamase producing Enterobacteriaceae; LOS, length of stay; MDRP, multi-drug-resistant Pseudomonas sp; OR, odds ratio. a All values were estimated from the index date to discharge; in all instances, reference group was patients who received timely appropriate therapy. Each outcome was adjusted for variables that were included in the inverse probability weighting: age, Charlson Comorbidity Index score, preindex LOS, resource intensity cost index, complicated urinary tract index, complicated intra-abdominal infection index, admission type, sex, asthma, congestive heart failure, chronic pulmonary disease, myocardial infarction+coronary heart disease, hemiplegia/paraplegia, immunocompromising conditions, cancer, malnutrition, peripheral vascular disease, chronic renal disease, type 2 diabetes, community-acquired infection vs. other source of infections, healthcare-associated infection, nosocomial infection, culture drawn in the intensive care unit, infection-related hospitalizations in prior 3 months. b P < 0.01.
FIGURE 1.
Association between delayed appropriate therapy and clinical and economic outcomes a stratified among patients with infections caused by (A) antibiotic-resistant and (B) antibiotic-susceptible pathogens. Covariates included in the final multivariate model were delayed appropriate therapy (yes vs. no), community-acquired infection versus other source of infections, culture drawn in ICU during index hospitalization (yes vs. no), preindex LOS, RI index-cost and other immunocompromising conditions. Abbreviations: ICU, intensive care unit; LOS, length of stay; OR, odds ratio; RD, relative difference; RI, resource intensity. a Each outcome was adjusted for variables that were included in the inverse probability weighting: age, Charlson Comorbidity Index score, preindex LOS, resource intensity cost index, complicated urinary tract index, complicated intra-abdominal infection index, admission type, sex, asthma, congestive heart failure, chronic pulmonary disease, myocardial infarction+coronary heart disease, hemiplegia/paraplegia, immunocompromising conditions, cancer, malnutrition, peripheral vascular disease, chronic renal disease, type 2 diabetes, community-acquired infection versus other source of infections, healthcare-associated infection, nosocomial infection, culture drawn in the intensive care unit, infectionrelated hospitalizations in prior 3 months. Assessed from index date to date of discharge.
outcome but as a composite of in-hospital death/discharge to hospice, because of potential "immortal time bias" resulting from the way in which delayed appropriate therapy was defined. Timing of appropriate therapy was assessed over the 3-day period beginning with the index date. Although patients who received antibiotic(s) with microbiological activity against the causal pathogen(s) within this window (i.e., on index date, day 2 or day 3) were deemed to have received timely treatment, those who did not receive appropriate therapy but died or were transferred to other healthcare institutions within this period were excluded. This could lead to selection bias with regard to mortality because only patients who remained alive for ≥3 days could be determined to have received delayed appropriate therapy, potentially underestimating the risk of mortality. Regardless, as noninclusion of discharge to hospice is known to cause underestimation of mortality risk, 21, 22 the composite outcome of in-hospital mortality and discharge to hospice is thought to be a more accurate measure.
Second, appropriateness of therapy was ascertained from microbiological susceptibility testing. For a patient to be defined as having timely appropriate therapy, they had to receive ≥1 antibiotic(s) with microbiological activity against all pathogens identified on the index culture and this included all Gram-negative pathogens and any other causal pathogens. Although we considered both Gram-negative and Gram-positive pathogens identified on index culture to assess appropriateness of therapy, we did not include mixed infections as a covariate in the analyses. The objective of this study was to mitigate the influence of antibiotic resistance status when evaluating the association between timely appropriate therapy independently from outcomes among patients with Gramnegative infections. Future studies are needed to determine whether mixed Gram-positive and Gram-negative pathogens alter the associations observed in this study.
Third, not all identified pathogens were tested against the antimicrobial(s) administered; therefore, algorithms were developed to ascertain appropriateness of treatment for a small percentage of patients. Fourth, the database does not contain detailed information on the severity of infection (e.g., fever, white blood cell count, oxygen levels [hospital-acquired pneumonia-specific], Acute Physiology and Chronic Health Evaluation scores). Although we were able to derive measures to serve as proxies for severity (e.g., resource intensity index, whether the patient was in the intensive care unit on the index date), the degree to which differences in outcomes were attributable to infection with resistant pathogens versus overall severity of infection is unclear. Fifth, data regarding services and medications received postdischarge were incomplete in the Premier database. Because of this, we limited the outcomes to those observed in the hospital or reported at discharge, and may have underestimated the duration of therapy as well as the costs and charges that accrued with outpatient therapy. Sixth, the database does not record the time of administration, so a patient who began antibiotic therapy at 12:01 AM and another who began therapy at 11:59 PM would both be considered to have received 1 day of treatment on a given day. Consequently, a 3-day period was used to define empiric therapy, which might have led to an "empiric" classification for some antibiotics that were in fact used as second-line therapy. Finally, although a strength of the current analysis is that it included more than 55,000 patients treated in approximately 150 hospitals throughout the United States, the database represents a convenience-and not a randomsample, which could result in estimates with unknown biases.
This retrospective analysis demonstrated that in "real world" hospital settings, delayed appropriate therapy was independently associated with poorer outcomes compared with timely appropriate therapy among hospitalized patients with serious infections due to Gram-negative bacteria, regardless of resistance status. Delayed appropriate therapy was the primary factor that influenced clinical and economic outcomes, suggesting that timely initial therapy coverage impacts clinical and economic outcomes more than the specific pathogen. Results of these analyses therefore suggest that better methods of early pathogen identification can reduce time to appropriate therapy, thereby improving outcomes and reducing in-hospital costs among hospitalized patients with serious infections due to Gram-negative bacteria. Our findings also highlight the need to shift current treatment practices away from antibiotic escalation strategies that contribute to delayed appropriate therapy and toward early, relatively aggressive and comprehensive antibiotic therapy in patients at risk for serious Gram-negative infections. As part of this proposed practice, clinicians need to deescalate or streamline therapy once culture and susceptibility data are available, and, when possible, to minimize the duration of use of broadspectrum antibiotics. Otherwise, prolonged overuse of broad-spectrum antibiotics will exacerbate the growing resistance problems and limit the future utility of current antibiotics.
